US OptionsDetailed Quotes

PCRX240517C27500

Watchlist

3.70
0.000.00%

15min DelayClose May 16 13:53 ET

0.00High0.00Low

Pacira BioSciences Stock Discussion

Moomoo AI

Mar 14 21:53

Recent insider share sale and lack of insider buying in the past year may concern investors. Despite some alignment between management and smaller shareholders, caution is advised due to recent insider selling activity.

Pacira BioSciences Independent Director Gary Pace Sells 85% Of Holding

Moomoo AI

Feb 4 23:04

Pacira BioSciences' moderate net income growth is seen as a positive despite a low ROE. The growth could be due to good management decisions or a low payout ratio, as it doesn't pay dividends. Analysts predict future earnings momentum.

Should Weakness in Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Moomoo AI

Jan 9 22:22

Multiple insiders selling shares over the past year could be a red flag. However, insider ownership level shows alignment between management and smaller shareholders. Lack of insider purchases in the past year calls for caution.

Pacira BioSciences Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution

Moomoo AI

Nov 25, 2023 02:47

The market seems to tolerate EPS decline but last year's worse-than-average performance may indicate long term investor concerns.

The Three-year Earnings Decline Is Not Helping Pacira BioSciences' (NASDAQ:PCRX Share Price, as Stock Falls Another 4.3% in Past Week

vincentts

Oct 12, 2021 16:07

$Pacira BioSciences(PCRX.US)$ $Flexion Therapeutics Inc(FLXN.US)$ On October 12, Pacira BioSciences announced that it has entered into a definitive agreement to acquire Flexion Therapeutics For $8.50 per share, or approximately $430 million, in cash to enhance its non-opioid pain portfolio. The deal also includes contingent valuable rights worth up to $8.00 per share, which are tied to Zilretta sales targets and FDA approvals for FX201 and FX301.

No comment yet